Literature DB >> 2865517

Acute myelogenous leukaemia with c-myc amplification and double minute chromosomes.

K Alitalo, K Saksela, R Winqvist, R Alitalo, J Keski-Oja, M Laiho, M Ilvonen, S Knuutila, A de la Chapelle.   

Abstract

Cytogenetic analysis of bone-marrow cells from a woman with preleukaemia showed numerous mitoses with trisomy 4 and double minute chromosomes. These abnormalities were later seen in blood cells during subsequent acute myeloid leukaemia (AML). Complete remission was achieved with three courses of doxorubicin, cytosine arabinoside, and prednisone. A further clonal abnormality, trisomy 6, was seen in leukaemic cells after the first relapse. Analyses of total DNA from the peripheral-blood cells during relapse showed that the c-myc oncogene was amplified about 30-fold in the leukaemic cells. The N-myc, c-mos, and c-myb oncogenes showed only single-copy signals. On average about two copies of c-myc resided on each dmin chromosome. The finding of amplification of a cellular oncogene (c-myc) in fresh AML cells containing double minute chromosomes suggests that clonal evolution of some leukaemia cell populations may involve selection for increased dosage of oncogenes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2865517     DOI: 10.1016/s0140-6736(85)90907-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  9 in total

Review 1.  Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype.

Authors:  Krzysztof Mrózek
Journal:  Semin Oncol       Date:  2008-08       Impact factor: 4.929

Review 2.  Gadd45 stress sensors in malignancy and leukemia.

Authors:  Dan A Liebermann; Jennifer S Tront; Xiogen Sha; Ksushiki Mukherjee; Alisha Mohamed-Hadley; Barbara Hoffman
Journal:  Crit Rev Oncog       Date:  2011

3.  Identification of rapid turnover transcripts overexpressed in thyroid tumors and thyroid cancer cell lines: use of a targeted differential RNA display method to select for mRNA subsets.

Authors:  R Gonsky; J A Knauf; R Elisei; J W Wang; S Su; J A Fagin
Journal:  Nucleic Acids Res       Date:  1997-10-01       Impact factor: 16.971

4.  Role of NR4A family members in myeloid cells and leukemia.

Authors:  Salix Boulet; Laure Le Corre; Livia Odagiu; Nathalie Labrecque
Journal:  Curr Res Immunol       Date:  2022-02-22

5.  Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation.

Authors:  Maro Ohanian; Carlos Bueso-Ramos; Chi Young Ok; Pei Lin; Keyur Patel; Mona Lisa Alattar; Joseph D Khoury; Uri Rozovski; Zeev Estrov; Yang O Huh; Jorge Cortes; Lynne V Abruzzo
Journal:  Cancer Genet       Date:  2015-06-25

6.  Transcriptomic and proteomic analysis of mouse radiation-induced acute myeloid leukaemia (AML).

Authors:  Christophe Badie; Agnieszka Blachowicz; Zarko Barjaktarovic; Rosemary Finnon; Arlette Michaux; Hakan Sarioglu; Natalie Brown; Grainne Manning; M Abderrafi Benotmane; Soile Tapio; Joanna Polanska; Simon D Bouffler
Journal:  Oncotarget       Date:  2016-06-28

7.  Expression Profiling of Ribosome Biogenesis Factors Reveals Nucleolin as a Novel Potential Marker to Predict Outcome in AML Patients.

Authors:  Virginie Marcel; Frédéric Catez; Caroline M Berger; Emeline Perrial; Adriana Plesa; Xavier Thomas; Eve Mattei; Sandrine Hayette; Pierre Saintigny; Philippe Bouvet; Jean-Jacques Diaz; Charles Dumontet
Journal:  PLoS One       Date:  2017-01-19       Impact factor: 3.240

8.  Pre-clinical evaluation of Minnelide as a therapy for acute myeloid leukemia.

Authors:  Bhuwan Giri; Vineet K Gupta; Brianna Yaffe; Shrey Modi; Pooja Roy; Vrishketan Sethi; Shweta P Lavania; Selwyn M Vickers; Vikas Dudeja; Sulagna Banerjee; Justin Watts; Ashok Saluja
Journal:  J Transl Med       Date:  2019-05-20       Impact factor: 5.531

Review 9.  Extrachromosomal Circular DNA: A New Target in Cancer.

Authors:  Pan Wu; Yuhang Liu; Ruijia Zhou; Lingyun Liu; Hongli Zeng; Fang Xiong; Shanshan Zhang; Zhaojian Gong; Wenling Zhang; Can Guo; Fuyan Wang; Ming Zhou; Xuyu Zu; Zhaoyang Zeng; Yong Li; Guiyuan Li; He Huang; Wei Xiong
Journal:  Front Oncol       Date:  2022-04-14       Impact factor: 5.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.